Image For Activity Cover
Empagliflozin Improves Outcomes in Patients with Heart Failure and Preserved Ejection Fraction Irrespective of Age (JACC July 2022-1)

The purpose of this study was to evaluate the interplay of age and empagliflozin effects in EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction).


Valentin Fuster, MD, PhD, MACC

CME Editor
Ragavendra R. Baliga, MD

Michael Böhm, MD 

Nicholas D. Gollop, MB BCH, PhD

Martina Brueckmann, MD

Important Dates

Date of Release: June 27, 2022
Term of Approval/Date of CME/MOC/ECME Expiration: June 26, 2023

Availability: Retired
Cost: FREE
Credit Offered:
No Credit Offered
Android App Download IOS App Download Powered By